Pfizer's RSV Vaccine Shows Strong Results in Immunocompromised Adults

Aug 12, 2024, 11:00 AM

Pfizer announced that its respiratory syncytial virus (RSV) vaccine, Abrysvo, has demonstrated a strong immune response in a late-stage study involving immunocompromised adults aged 18 and older. The study showed that a single dose of the vaccine produced robust antibodies against RSV-A and RSV-B, indicating potential benefits for adults at risk of severe RSV-related illness. The top-line results highlight the vaccine's efficacy in generating an immune response in this vulnerable population.